Cyclacel Pharmaceuticals, Inc.

NasdaqCM:CYCC Stock Report

Market Cap: US$2.0m

Cyclacel Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CYCC?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders83,3471.33%
Institutions369,7485.88%
General Public5,834,11092.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 645.9%.

Top Shareholders

Top 25 shareholders own 7.21% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
3.54%
Armistice Capital LLC
222,655US$70.7k66.2%no data
1.3%
Altium Capital Management LP
82,032US$26.0k0%0.01%
0.48%
Spiro Rombotis
30,000US$9.5k0%no data
0.27%
Brian Schwartz
16,707US$5.3k0%no data
0.26%
Paul McBarron
16,241US$5.2k0%no data
0.24%
Point72 Asset Management, L.P.
15,333US$4.9k0%no data
0.23%
Acadian Asset Management LLC
14,285US$4.5k0%no data
0.2%
UBS Asset Management AG
12,553US$4.0k-67%no data
0.17%
Geode Capital Management, LLC
10,598US$3.4k84%no data
0.092%
The Vanguard Group, Inc.
5,796US$1.8k0%no data
0.067%
Karin Walker
4,207US$1.3k0%no data
0.066%
Samuel Barker
4,155US$1.3k0%no data
0.065%
Christopher Henney
4,089US$1.3k0%no data
0.065%
Robert Jay Spiegel
4,073US$1.3k0%no data
0.064%
Tower Research Capital Europe Limited
4,010US$1.3k14.2%no data
0.062%
Kenneth Ferguson
3,875US$1.2k0%no data
0.03%
Schonfeld Strategic Advisors LLC
1,900US$603.10%no data
0.0026%
McIlrath & Eck, LLC
166US$52.7-80.1%no data
0.0021%
Activest Wealth Management, LLC
133US$42.30%no data
0.002%
Osaic Wealth, Inc. , Asset Management Arm
126US$39.90%no data
0.0013%
Morgan Stanley, Investment Banking and Brokerage Investments
80US$25.30%no data
0.00052%
Wells Fargo & Company, Securities and Brokerage Investments
33US$10.40%no data
0.00032%
SignatureFD, LLC
20US$6.40%no data
0.00024%
Bank of America Corporation, Asset Management Arm
15US$4.850%no data
0.00021%
Harbour Investments, Inc.
13US$4.20%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:39
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cyclacel Pharmaceuticals, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Kimberly LeeJanney Montgomery Scott LLC
Michael KingJMP Securities